Javascript must be enabled to continue!
Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort
View through CrossRef
Abstract
Objectives
Myositis-specific and associated autoantibodies are important biomarkers in routine clinical use. We assessed local testing performance for myositis autoantibodies by comparing line immunoassay (LIA) to protein radio-immunoprecipitation and identifying clinical characteristics associated with each myositis autoantibody in the MyoCite cohort.
Methods
Serum samples from patients within the MyoCite cohort, a well-characterized retro-prospective dataset of adult and juvenile idiopathic inflammatory myopathy (IIM) patients in Lucknow, India (2017–2020), underwent LIA at Sanjay Gandhi Postgraduate Institute of Medical Science (SGPGIMS), Lucknow. Immunoprecipitation of 147 IIM patients’ serum samples (125 adult-onset, 22 juvenile-onset) was conducted at the University of Bath, with researchers blind to LIA results. LIA performance was assessed against immunoprecipitation as the reference standard, measuring sensitivity, specificity and inter-rater agreement. Univariate and multivariate logistic regression determined clinical associations for specific myositis-specific autoantibodies.
Results
Immunoprecipitation identified myositis autoantibodies in 56.5% (n = 83) of patient samples, with anti-Jo1 (n = 16; 10.9%) as the most common, followed by anti-MDA5 (n = 14, 9.5%). While LIA showed good agreement for anti-Jo1, anti-PL7 and anti-PL12 (Cohen's κ 0.79, 0.83 and 1, respectively), poor agreement was observed in other subgroups, notably anti-TIF1γ (Cohen's κ 0.21). Strongly positive samples, especially in myositis-specific autoantibodies, correlated more with immunoprecipitation results. Overall, 59 (40.1%) samples exhibited non-congruence on LIA and immunoprecipitation, and κ values for LIAs for anti-TIF1γ, anti-Ku, anti-PmScl, anti-Mi2 and anti-SAE ranged between 0.21 and 0.60.
Conclusion
While LIA reliably detected anti-Jo1, anti-PL7, anti-PL12, anti-MDA5 and anti-NXP-2, it also displayed false positives and negatives. Its effectiveness in detecting other autoantibodies, such as anti-TIF1γ, was poor.
Oxford University Press (OUP)
Title: Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort
Description:
Abstract
Objectives
Myositis-specific and associated autoantibodies are important biomarkers in routine clinical use.
We assessed local testing performance for myositis autoantibodies by comparing line immunoassay (LIA) to protein radio-immunoprecipitation and identifying clinical characteristics associated with each myositis autoantibody in the MyoCite cohort.
Methods
Serum samples from patients within the MyoCite cohort, a well-characterized retro-prospective dataset of adult and juvenile idiopathic inflammatory myopathy (IIM) patients in Lucknow, India (2017–2020), underwent LIA at Sanjay Gandhi Postgraduate Institute of Medical Science (SGPGIMS), Lucknow.
Immunoprecipitation of 147 IIM patients’ serum samples (125 adult-onset, 22 juvenile-onset) was conducted at the University of Bath, with researchers blind to LIA results.
LIA performance was assessed against immunoprecipitation as the reference standard, measuring sensitivity, specificity and inter-rater agreement.
Univariate and multivariate logistic regression determined clinical associations for specific myositis-specific autoantibodies.
Results
Immunoprecipitation identified myositis autoantibodies in 56.
5% (n = 83) of patient samples, with anti-Jo1 (n = 16; 10.
9%) as the most common, followed by anti-MDA5 (n = 14, 9.
5%).
While LIA showed good agreement for anti-Jo1, anti-PL7 and anti-PL12 (Cohen's κ 0.
79, 0.
83 and 1, respectively), poor agreement was observed in other subgroups, notably anti-TIF1γ (Cohen's κ 0.
21).
Strongly positive samples, especially in myositis-specific autoantibodies, correlated more with immunoprecipitation results.
Overall, 59 (40.
1%) samples exhibited non-congruence on LIA and immunoprecipitation, and κ values for LIAs for anti-TIF1γ, anti-Ku, anti-PmScl, anti-Mi2 and anti-SAE ranged between 0.
21 and 0.
60.
Conclusion
While LIA reliably detected anti-Jo1, anti-PL7, anti-PL12, anti-MDA5 and anti-NXP-2, it also displayed false positives and negatives.
Its effectiveness in detecting other autoantibodies, such as anti-TIF1γ, was poor.
Related Results
5. All That glitters is not gold
5. All That glitters is not gold
Abstract
Introduction
Inflammatory muscle disease is a rare but well-recognised manifestation of systemic vasculitis. It can pre...
Metagenome-wide Association Study of Gut Microbiome Features for Myositis
Metagenome-wide Association Study of Gut Microbiome Features for Myositis
Abstract
Background: The clinical relevance and pathogenic role of gut microbiome in both myositis and its associated interstitial lung disease (ILD) are still unclear.The ...
P060 Unmasking myositis in a complex overlap syndrome
P060 Unmasking myositis in a complex overlap syndrome
Abstract
Introduction
Primary Sjögren’s Syndrome (pSS) is a chronic autoimmune condition primarily affecting exocrine gla...
Autoantibodies predict type 1 diabetes after gestational diabetes – a 23-year cohort study
Autoantibodies predict type 1 diabetes after gestational diabetes – a 23-year cohort study
ObjectiveTo study the predictive value of autoantibodies for type 1 (T1DM) and type 2 (T2DM) diabetes morbidity after gestational diabetes (GDM) in a 23-year follow-up study.Design...
Provocative Tests in Diagnosis of Thoracic Outlet Syndrome: A Narrative Review
Provocative Tests in Diagnosis of Thoracic Outlet Syndrome: A Narrative Review
Abstract
Thoracic outlet syndrome (TOS) is a group of conditions caused by the compression of the neurovascular bundle within the thoracic outlet. It is classified into three main ...
Cohort studies
Cohort studies
A cohort study is one in which the outcome (usually disease status) is ascertained for groups of individuals defined on the basis of their exposure. At the time exposure status is ...
P034 Checkpoint inhibitor-induced coexisting myositis and myasthenia gravis in a malignant mesothelioma patient: a case report
P034 Checkpoint inhibitor-induced coexisting myositis and myasthenia gravis in a malignant mesothelioma patient: a case report
Abstract
Background/Aims
Nivolumab & ipilimumab are immune checkpoint inhibitors (ICIs) and combination therapy has shown ef...
Diagnostic delay of Myositis: protocol for an integrated systematic review
Diagnostic delay of Myositis: protocol for an integrated systematic review
Abstract
Idiopathic inflammatory myopathies (IIM) described as “inflammatory myositis”, are a heterogeneous group of rare muscular autoimmune diseases characterized...

